NCT02387216

A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC

SHERLOC: A Phase 2 Study of MM-121 in Combination With Docetaxel Versus Docetaxel Alone in Patients With Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Merrimack Pharmaceuticals Inc.)

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 153 (actual)
• Sponsor: Elevation Oncology · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether the combination of MM-121 plus docetaxel is more effective than docetaxel alone in regards to PFS in patients with heregulin-positive NSCLC.

Detailed description

This study is a randomized, open-label, international, multi-center, phase 2 study in patients with Heregulin-positive NSCLC histologically classified as adenocarcinoma that have progressed following no more than two systemic therapies for locally advanced or metastatic disease, one of which must have been a platinum containing regimen. All patients will initially be screened for heregulin status. Eligible patients will be randomized to receive MM-121 in combination with docetaxel versus docetaxel alone.

Conditions

• Non-Small Cell Lung Cancer
• NSCLC
• Adenocarcinoma
• Heregulin

Interventions

Type	Name	Description
DRUG	MM-121	Investigational, fully human antibody targeting and inhibiting ErbB3
DRUG	Docetaxel	approved chemotherapy treatment for NSCLC

Timeline

• Start date: 2015-02-01
• Primary completion: 2019-01-02
• Completion: 2019-01-02
• First posted: 2015-03-12
• Last updated: 2021-10-12
• Results posted: 2021-10-12

Locations

35 sites across 6 countries: United States, Canada, France, Germany, Hungary, Spain